PT  - JOURNAL ARTICLE
AU  - YUICHI OZAWA
AU  - KEIGO KODA
AU  - DAISUKE AKAHORI
AU  - TAKASHI MATSUI
AU  - HIROTSUGU HASEGAWA
AU  - TAKUYA KAKUTANI
AU  - TUSUKE AMANO
AU  - MASAYUKI TANAHASHI
AU  - HIROSHI NIWA
AU  - YUKIHIRO KUNIMOTO
AU  - KAZUNARI YAMADA
AU  - KOSHI YOKOMURA
AU  - TAKAFUMI SUDA
TI  - Preexisting Interstitial Lung Disease and Lung Injury Associated with Irinotecan in Patients with Neoplasms
AID  - 10.21873/anticanres.12939
DP  - 2018 Oct 01
TA  - Anticancer Research
PG  - 5937--5941
VI  - 38
IP  - 10
4099  - http://ar.iiarjournals.org/content/38/10/5937.short
4100  - http://ar.iiarjournals.org/content/38/10/5937.full
SO  - Anticancer Res2018 Oct 01; 38
AB  - Background/Aim: The aim of this study was to reveal risk factors for lung injury following irinotecan administration for the treatment of neoplasms. Patients and Methods: This study included 204 patients who received irinotecan from October 2005 to November 2014 and had evaluable chest CT images before initiation of irinotecan. Results: Six (2.9%) patients developed lung injury and, of these, 2 had preexisting interstitial lung disease (pre-ILD). The frequency of lung injury in patients with pre-ILD was 11% (2 of 19) while that in patients without pre-ILD was 2.2%. Risk factor analysis for the lung injury showed pre-ILD was the most predictable factor [odds ratio (OR) 5.00, p=0.07]. Combination with other agents, origin of neoplasms (lung or not), initial dose or minimum interval were not observed to be related to risk. Conclusion: The risk of lung injury with irinotecan was high when pre-ILD was present and the risk was comparable with previously reported other agents.